| Identification | Back Directory | [Name]
2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- | [CAS]
1675201-83-8 | [Synonyms]
T3655
BMS-1
CS-2413
avelumab/PD-L1
PD-1PD-L1 inhibitor
PD1-PDL1 inhibitor 1
PD-1/PD-L1 inhibitor 1(C1)
BMS-1 (PD-1/PD-L1 inhibitor 1)
PD1-PDL1 inhibitor 1 (PD1-PDL1-IN1)
PD1/PDL1 INHIBITOR 1;PD 1/PD L1 INHIBITOR 1
(2S)-1-{2,6-Dimethoxy-4-[(2-methyl-3-biphenylyl)methoxy]benzyl}-2-piperidinecarboxylic acid
(2S)-1-[[2,6-Dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-2-piperidinecarboxylic acid
2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- | [Molecular Formula]
C29H33NO5 | [MDL Number]
MFCD28978741 | [MOL File]
1675201-83-8.mol | [Molecular Weight]
475.58 |
| Chemical Properties | Back Directory | [Boiling point ]
630.2±55.0 °C(Predicted) | [density ]
1.182±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
Soluble in DMSO (up to at least 25 mg/ml) or in Ethanol (up to 20 mg/ml) | [form ]
solid | [pka]
2.34±0.20(Predicted) | [color ]
White | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| Hazard Information | Back Directory | [Description]
PD-1/PD-L1 Inhibitor 1 (1675201-83-8) inhibits (IC50 = <100nM) the formation of the PD-1/PD-L1 complex via binding to PD-L1 and inducing dimerization.1 | [Uses]
BMS-1 is a PD-L1 inhibitor which is used in combination with LIF inhibitors for the treatment of cancers. | [in vitro]
pd-1/pd-l1 inhibitor 1 has been identified to be a potent and selective small molecule inhibitor blocking the interaction of programmed cell death protein 1 (pd-1) with its ligand protein (pd-l1). pd-1/pd-l1 inhibitor 1 was also found to act as an immunomodulator. in preclinical studies, pd-1/pd-l1 inhibitor 1 was able to block pd-1/pd-ll interactions with an ic50 value between 6 and 100 nm, which was measured by a homogenous time-resolved fluorescence (htrf) binding assay. thus, pd-1/pd-l1 inhibitor 1 might potentially be used for the treatment of cancer as well as infectious diseases, such as hepatitis c [1]. | [in vivo]
BMS-1 (500 μg/mL; 100 μL; i.p.) significantly increases the survival rates of the mVEGF165b group and mVEGF165b + MUC1 group[3].
| Animal Model: | BALB/c mice with EMT6 cells[3] | | Dosage: | 500 μg/mL; 100 μL | | Administration: | I.p. | | Result: | Increased the survival rates of the mVEGF165b group and mVEGF165b + MUC1 group.
mVEGF165b combined with MUC1 results significant retardation of the tumor growth. |
| [IC 50]
0.006-0.10 μm | [storage]
Store at -20°C | [References]
1) Chupak?et al. (2015), Compounds Useful as Immunomodulators; WO2015/034820 |
|
|